2023-509035-30-00已完成1 期
[HIBOU] : A phase I, single-center, randomized, double-blind, single-dose escalation, placebo-controlled clinical study to evaluate the safety, tolerability and pharmacokinetics of IMP21052 administered intravenously in three groups of healthy male and female volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Chef de bureau
Scientific
Direction Centrale Du Service De Sante Des Armees
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO- CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF TQS-168 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS2023-504746-54-00Tranquis Therapeutics Inc.16
招募中
1 期
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours2023-508126-95-00Karolinska University Hospital30
已完成
4 期
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Lacosamide tablets USP 200 mg, manufactured by Sun Laboratories Industries Limited, India with Vimpat (Lacosamide) 200 mg film-coated tablets, Marketing Authorisation Holder UCB Pharma S.A., Belgium, in healthy adult, human subjects under fasting condition.2023-507991-32-00Sun Pharmaceutical Industries Limited32
已完成
1 期
A first-in-human phase 1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of three dose levels of the OVX033 vaccine, after intramuscular administration in healthy subjects aged 18-49 years2023-506396-94-00Osivax48
招募中
4 期
A Phase I double blinded, single-center, randomized, crossover study comparing the PK, PD, safety and tolerability of a single IV dose (1µg/kg) of LB-0702 and Nplate® in healthy volunteers.2024-518285-27-00Laboratorio Reig Jofre S.A.34